生物制药创新领域重拾发展动力

Progress in Recapturing Momentumin Biopharma Innovation Introduction The life sciences innovation ecosystem has continued to evolve and expand asindustry adapts to a complex and dynamic range of geopolitical, technologicaland social uncertainties, and investment continues to flow into the sector.Innovative science has also grown in parallel, as evidenced by an increasingproportion of novel therapeutic modalities in clinical trials and by innovativeproducts receiving regulatory approval and reaching patients — with multipleimportant cell and gene therapy drugs having achieved recent success,alongside new options for historically challenging indications. Despite theseadvances, improving the efficiency of R&D remains an important objective forbiopharmaceutical companies and significant opportunities exist to reducemedicine development times and increase probabilities of success. This report assesses the trends in R&D funding, clinicaltrial activity, and new drug approvals and launches. Italso examines the efficiency and productivity of clinicaldevelopment, using a refreshed Clinical ProgramProductivity Index, while also providing insights oncontributing factors and enablers. Operationallyaddressable cycle time components are investigatedby examining clinical trial timelines in the broadercontext of a typical medicine development program,demonstrating critical within- and between-trialcomponents that can be targeted to acceleratedevelopment. The continued significance of emergingbiopharma companies and of geographical shifts inclinical trial activity are revisited throughout. based on proprietary IQVIA databases and/or third-partyinformation. No proprietary sponsor trial informationis presented. The contributions to this report from Taskin Ahmed,Lucy Haggerty, Srinidhi BC, Tanya Bhardwaj,Chris Bamford, Rachael Fones, Julia Kern, BhagyashreeNawar, Urvashi Porwal, Jamie Pritchett, and dozens ofothers at IQVIA are gratefully acknowledged. Find Out More If you wish to receive future reports from the IQVIAInstitute for Human Data Science or join our mailing list,visit iqviainstitute.org. The research included in this report was undertakenindependently by the IQVIA Institute for HumanData Science as a public service, without industry orgovernment funding. The analytics in this report are MURRAY AITKENExecutive DirectorIQVIA Institute for Human Data Science REFERENCING THIS REPORT Please use this format when referencing content from this report:Source: IQVIA Institute for Human Data Science. Global Trends in R&D 2025: Progress in recapturing momentum in biopharma innovation.March 2025.Available from www.iqviainstitute.org ©2025 IQVIA and its affiliates. All reproduction rights, quotations, broadcasting, publications reserved. No part of this publication may be reproduced ortransmitted in any form or by any means, electronic or mechanical, including photocopy, recording, or any information storage and retrieval system, withoutexpress written consent of IQVIA and the IQVIA Institute. Global Trends in R&D 2025: Progress in Recapturing Momentum in Biopharma Innovation Table of Contents Overview2R&D funding5Clinical trial activity14New drug approvals and launches36Clinical development productivity51Productivity enablers72Notes on sources86Methodologies87References89About the authors90About the Institute92 Overview Total R&D expenditure of large pharmaceuticalcompanies continued to increase in 2024, both inabsolute terms (reaching $190Bn, up from $163Bn in2023) and as a percentage of sales, exceeding 25%for the first time. R&D FUNDING Biopharma funding levels in the past year continued toincrease following the post-pandemic rebound of 2023,with growth contributions coming from IPOs, follow-onfunding, and other public and private sources. Excludingthe 2020 and 2021 heights seen during the pandemic,funding reached a 10 year high of $102Bn in 2024— a substantial increase on the 2023 figure of $71Bn. CLINICAL TRIAL ACTIVITY The total volume of clinical trial starts stabilized in2024 after the year-on-year declines seen in 2022and 2023, reaching 5,318 — a number remarkablysimilar to the 5,316 pre-pandemic count in 2019 andslightly above the 5,302 total of 2023. The short-termvolatility introduced by COVID-19 trials since 2019 hasbeen partly counterbalanced by increasing trials fromChina-headquartered companies and recent uplifts fromEBP and larger companies, especially in Phase I. In contrast, the volume of R&D deals betweenpharmaceutical companies declined in 2024, continuingthe downward trend that began in 2022. More than halfof the 1,016 deals made in 2024 were between emergingbiopharma (EBP) companies, with the majority of theremainder involving EBP deals with larger companies.Partnerships between larger companies remainedrelatively rare, accounting for just over one in ten R&Ddeals. The volume of M&A deals also declined between2023 and 2024, but the median value of these dealsincreased dramatically fro